(Q37910914)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

0 references

1 reference

chronic lymphocytic leukemia

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Rachel E Hayden

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Guy Pratt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Claudia Roberts

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Mark T Drayson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

1 reference

23 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

537-549

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Mechanisms of B-cell lymphoma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

B cell follicles and antigen encounters of the third kind

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

T cells and follicular dendritic cells in germinal center B-cell formation and selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Human splenic marginal zone B cells lack expression of activation-induced cytidine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Defining origins of malignant B cells: a new circulating normal human IgM(+)D(+) B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Separate cell culture conditions to promote proliferation or quiescent cell survival in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Chronic B cell malignancies and bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The cellular biology of B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Sympathetic innervation of lymph nodes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Multiple neuropeptides in nerves supplying mammalian lymph nodes: messenger candidates for sensory and autonomic neuroimmunomodulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Sympathetic modulation of immunity: relevance to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The sympathetic nervous system modulates CD4(+)FoxP3(+) regulatory T cells via a TGF-beta-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Germinal centres: role in B-cell physiology and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The biology of the germinal center

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

How B and T cells talk to each other

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Release of clonal block in B cell chronic lymphocytic leukaemia by engagement of co-operative epitopes on CD40.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Microenvironmental interactions and survival of CLL B-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

CD40 regulates the processing of NF-kappaB2 p100 to p52

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Apoptosis induces Bcl-XS and cleaved Bcl-XL in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Can we afford to let sleeping dogs lie?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Chronic lymphocytic leukemia: treatment options for patients with refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

On the TRAIL of a new therapy for leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Abnormal T-cell function in B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Management of patients with chronic lymphocytic leukemia treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.610014

10.3109/10428194.2011.610014

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21812539%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference